title: Serious renal impairment occurs rarely with use of tenofovir DF.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection.
  
  
  METHODS
  The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewed. Data collected included demographics, concurrent antiretrovirals, other concurrent medications, CD4 counts and HIV-1 viral loads, and serum creatinine values while on tenofovir DF. Data collection was truncated at 6 months.
  
  
  RESULTS
  Baseline serum creatinine (SCr) was 1.0 mg/dL, with a calculated creatinine clearance (CLCr) of 95.2 mL/min (using the Cockroft-Gault equation). There was no significant change in SCr or CLCr at 12 weeks (1.1 mg/dL and 92.7 mL/min, respectively) or 24 weeks (1.1 mg/dL and 92.9 mL/min, respectively). All three patients with grade 2 increases in SCr had other medical reasons for an increased SCr (one patient each had indinavir-associated nephrolithiasis, lactic acidosis, and pancreatitis). No patients experienced any complications from these increases in SCr.
  
  
  CONCLUSIONS
  Increases in SCr and CLCr within the first 6 months of tenofovir DF therapy were rare. Although no clinical nephrotoxicity was observed, continued observation of renal function is warranted in patients predisposed to renal impairment.
authors.affiliation: Western University of Health Sciences College of Pharmacy, Pomona, California 91766, USA. jscott@laglc.org
authors.forename: James D
authors.initials: JD
authors.lastname: Scott
authors.forename: Peter R
authors.initials: PR
authors.lastname: Wolfe
authors.forename: Robert K
authors.initials: RK
authors.lastname: Bolan
authors.forename: Bill
authors.initials: B
authors.lastname: Guyer
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002140:California; D003404:Creatinine / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000097:blood / Q000139:chemically induced*; D012189:Retrospective Studies; D000068698:Tenofovir
chemical_list: D063065:Organophosphonates; D000068698:Tenofovir; D003404:Creatinine; D000225:Adenine